INC Research Selects TransPerfect's Trial Interactive Technology as its eTMF Solution
TransPerfect, a provider of e-clinical technologies to the life sciences industry, announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution. Trial Interactive is a secure, web-based platform that reduces the redundancies inherent in paper-based TMF management.
"We chose Trial Interactive as our eTMF solution because it offers the greatest compatibility with current and potential customers,” said Todd Esporas, Executive Director of Clinical Development Services at INC Research. As one of the top 10 global CROs, optimizing the collection and management of TMFs worldwide is a critical task for INC Research. Trial Interactive enables INC Research to deliver trials more efficiently by allowing real-time access to global project documentation, eliminating much of the travel and shipping associated with TMF reviews and reconciliation, and providing a real-time metrics dashboard to enhance communications with customers and stakeholders. Trial Interactive’s interface is available in more than 20 languages, which will enable INC Research to deploy the solution in the local language of the end user, making it ideal for global study teams, sponsors, and investigative site personnel involved in the conduct of multinational clinical trials.
Michael Smyth, General Manager of TransPerfect’s Life Science Solutions division, stated, “We’re very proud that INC Research has chosen Trial Interactive as its eTMF solution. INC’s global reach and commitment to utilizing technology should only serve to benefit their study sponsors as they seek to become more efficient in conducting global clinical trials.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
